杜匹单抗联合口服全身免疫调节剂治疗资源有限的有色儿童中重度特应性皮炎:一个病例系列

IF 0.2 Q4 DERMATOLOGY
Siti Nuraihan, MN Azmi, Sabeera Begum, Kin Fon Leong
{"title":"杜匹单抗联合口服全身免疫调节剂治疗资源有限的有色儿童中重度特应性皮炎:一个病例系列","authors":"Siti Nuraihan, MN Azmi, Sabeera Begum, Kin Fon Leong","doi":"10.4103/ijpd.ijpd_94_22","DOIUrl":null,"url":null,"abstract":"Abstract Subcutaneous dupilumab, with or without topical therapy, is clinically proven to treat children with moderate-to-severe atopic dermatitis (AD). However, this well-researched biologic for AD in children is still among the most expensive medication in the world and not widely available in resource-poor areas. We share our experience managing four children with severe AD, aged 3 to 11, who poorly responded to oral systemic immunomodulators but successfully achieved rapid clinical remission when combined with subcutaneous dupilumab. No loading doses were administered to patients in this case series, and the maintenance dosages used were lower than the manufacturer’s recommendations. This case series illustrates that oral immunomodulators in combination with subcutaneous dupilumab therapy are efficacious, safe, tolerable, and cost-effective for children with moderate-to-severe AD. This treatment strategy can be considered an alternative for children with AD recalcitrant to other available treatment options, especially when AD management is challenging in limited resource settings.","PeriodicalId":13275,"journal":{"name":"Indian Journal of Paediatric Dermatology","volume":"12 1","pages":"0"},"PeriodicalIF":0.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dupilumab as a Combination Therapy to Oral Systemic Immunomodulators for Moderate-to-Severe Atopic Dermatitis for Skin of Color Children in Resource-Limited Setting: A Case Series\",\"authors\":\"Siti Nuraihan, MN Azmi, Sabeera Begum, Kin Fon Leong\",\"doi\":\"10.4103/ijpd.ijpd_94_22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Subcutaneous dupilumab, with or without topical therapy, is clinically proven to treat children with moderate-to-severe atopic dermatitis (AD). However, this well-researched biologic for AD in children is still among the most expensive medication in the world and not widely available in resource-poor areas. We share our experience managing four children with severe AD, aged 3 to 11, who poorly responded to oral systemic immunomodulators but successfully achieved rapid clinical remission when combined with subcutaneous dupilumab. No loading doses were administered to patients in this case series, and the maintenance dosages used were lower than the manufacturer’s recommendations. This case series illustrates that oral immunomodulators in combination with subcutaneous dupilumab therapy are efficacious, safe, tolerable, and cost-effective for children with moderate-to-severe AD. This treatment strategy can be considered an alternative for children with AD recalcitrant to other available treatment options, especially when AD management is challenging in limited resource settings.\",\"PeriodicalId\":13275,\"journal\":{\"name\":\"Indian Journal of Paediatric Dermatology\",\"volume\":\"12 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Paediatric Dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ijpd.ijpd_94_22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Paediatric Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijpd.ijpd_94_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

皮下注射dupilumab,有或没有局部治疗,临床证明可治疗中度至重度特应性皮炎(AD)儿童。然而,这种经过充分研究的治疗儿童阿尔茨海默病的生物制剂仍然是世界上最昂贵的药物之一,在资源贫乏的地区也没有广泛使用。我们分享了我们治疗4名患有严重AD的儿童的经验,年龄在3至11岁之间,他们对口服全身免疫调节剂反应不佳,但在联合皮下杜匹单抗后成功地实现了快速临床缓解。在本病例系列中,没有给患者施加负荷剂量,使用的维持剂量低于制造商的推荐剂量。该系列病例表明,口服免疫调节剂联合皮下杜匹单抗治疗对中重度AD患儿有效、安全、耐受且具有成本效益。这种治疗策略可以被认为是阿尔茨海默病儿童对其他可用治疗方案难以抗拒的一种替代方案,特别是当阿尔茨海默病管理在资源有限的情况下具有挑战性时。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Dupilumab as a Combination Therapy to Oral Systemic Immunomodulators for Moderate-to-Severe Atopic Dermatitis for Skin of Color Children in Resource-Limited Setting: A Case Series
Abstract Subcutaneous dupilumab, with or without topical therapy, is clinically proven to treat children with moderate-to-severe atopic dermatitis (AD). However, this well-researched biologic for AD in children is still among the most expensive medication in the world and not widely available in resource-poor areas. We share our experience managing four children with severe AD, aged 3 to 11, who poorly responded to oral systemic immunomodulators but successfully achieved rapid clinical remission when combined with subcutaneous dupilumab. No loading doses were administered to patients in this case series, and the maintenance dosages used were lower than the manufacturer’s recommendations. This case series illustrates that oral immunomodulators in combination with subcutaneous dupilumab therapy are efficacious, safe, tolerable, and cost-effective for children with moderate-to-severe AD. This treatment strategy can be considered an alternative for children with AD recalcitrant to other available treatment options, especially when AD management is challenging in limited resource settings.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
27
审稿时长
25 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信